Camizestrant Clinical Trials

7 actively recruiting trials across 5 locations

▲ +1 trial since June 2026

Also known as: AZD9833

Pipeline

Phase 2: 2Phase 3: 4Phase 1/2: 1

Top Sponsors

AstraZeneca6
MedSIR1

Indications

Breast Cancer7
Cancer7
Breast Cancer, Early Breast Cancer2
Advanced Breast Cancer2
ER-Positive HER2-Negative Breast Cancer1

St Louis, Missouri2 trials

A First-in-human Dose Escalation and Expansion Study to Evaluate the Safety, and Tolerability of AZD8421 Alone or in Combination in Participants With Selected Advanced or Metastatic Solid Tumors

Research Site

Phase 1/2

Study to Evaluate the Safety and Tolerability of Camizestrant in Combination With Atirmociclib in Women With Advanced Breast Cancer

Research Site

Phase 2

Other1 trial

Efficacy and Safety of Camizestrant Plus Ribociclib in Patients With Breast Cancer

Phase 2

Birmingham, Alabama1 trial

A Study of Camizestrant in ER+/HER2- Early Breast Cancer After at Least 2 Years of Standard Adjuvant Endocrine Therapy

Research Site

Phase 3

Dothan, Alabama1 trial

An Adjuvant Endocrine-based Therapy Study of Camizestrant (AZD9833) in ER+/HER2- Early Breast Cancer (CAMBRIA-2)

Research Site

Phase 3

Gilbert, Arizona1 trial

Saruparib (AZD5305) Plus Camizestrant Compared With CDK4/6 Inhibitor Plus Endocrine Therapy or Plus Camizestrant in HR-Positive, HER2-Negative (IHC 0, 1+, 2+/ ISH Non-amplified), BRCA1, BRCA2, or PALB2m Advanced Breast Cancer

Research Site

Phase 3

Duarte, California1 trial

A Phase IIIb Study to Evaluate Camizestrant Plus Ribociclib in ER-positive, HER2-negative Advanced Breast Cancer

Research Site

Phase 3

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.